| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Cancer Research UK Edinburgh Oncology Unit, Western General Hospital, Edinburgh EH4 2XU [L. M. R. G., K. G. M., A. M., J. M. S., J. F. S., S. P. L.], and ICRF Oncology Unit, Imperial College School of Medicine, London W12 ONN [W. J. G.], United Kingdom
Purpose: To investigate the expression and function of neuregulin (NRG) isoforms in ovarian cancer cell lines and tumor samples.
Experimental Design: Expression of NRG-1
and NRG-1ß proteins were detected by immunohistochemistry and mRNA by RT-PCR. erbB receptor levels and downstream signaling proteins were measured by Western blot analysis.
Results: Expression of NRG-1 and NRG-1ß proteins were detected by immunohistochemistry in 46 of 53 (87%) and 41 of 53 (77%) ovarian carcinomas, respectively. Serous carcinomas express higher levels of NRG-1 than endometrioid carcinomas (P = 0.017). NRG mRNA was detected by RT-PCR in 20 of 24 (83%) of ovarian carcinomas and eight of nine (89%) ovarian cancer cell lines. NRG-1 stimulated the growth of 5 of 14 cell lines whereas NRG-1ß stimulated 7 of 14 cell lines. The magnitude of NRG growth response was significantly associated with erbB2 expression levels. NRG-1 and -1ß (1 nM) growth-stimulated cell lines PE01 and PE06 demonstrated increased tyrosine phosphorylation of erbB2 and elevated tyrosine phosphorylation of ERK1 and ERK2. In contrast, the SKOV-3 cell line, the growth of which was unaffected, did not show these downstream responses. An anti-erbB3 receptor antibody (clone H3.105.5) blocked NRG-1ß growth changes and signaling in these cell lines. Conversely, the anti-erbB4 antibody (clone H4.72.8) enhanced NRG-ß1 growth stimulation. Herceptin also inhibited growth.
Conclusions: With NRG expression in the majority of ovarian carcinomas and cell lines, there is the potential for autocrine regulation of cell growth. Interfering with ligand-receptor interactions by receptor blocking antibodies suggests erbB3 is primarily involved in NRG-1ß-induced proliferation, with erbB4 having a more complex role.
This article has been cited by other articles:
|
|
 |
|
  J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella Neuregulins and Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3237 - 3241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E Hynes ErbB Receptors in Cancer: HER2/ErbB2 as a Therapeutic Target Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Newbery, D. H. Loh, J. E. O'Donoghue, V. A. L. Tomlinson, Y.-Y. Chau, J. A. Boyd, J. H. Bergmann, D. Brownstein, and C. M. Abbott Translation Elongation Factor eEF1A2 Is Essential for Post-weaning Survival in Mice J. Biol. Chem., September 28, 2007; 282(39): 28951 - 28959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y. W. Bourguignon, E. Gilad, and K. Peyrollier Heregulin-mediated ErbB2-ERK Signaling Activates Hyaluronan Synthases Leading to CD44-dependent Ovarian Tumor Cell Growth and Migration J. Biol. Chem., July 6, 2007; 282(27): 19426 - 19441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sawada, A. R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, A. R. Becker, M. A. Turkyilmaz, R. Salgia, S. D. Yamada, G. F. Vande Woude, et al. c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion Cancer Res., February 15, 2007; 67(4): 1670 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mullen, D. A. Cameron, M. Hasmann, J. F. Smyth, and S. P. Langdon Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling Mol. Cancer Ther., January 1, 2007; 6(1): 93 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Macleod, P. Mullen, J. Sewell, G. Rabiasz, S. Lawrie, E. Miller, J. F. Smyth, and S. P. Langdon Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer Cancer Res., August 1, 2005; 65(15): 6789 - 6800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Pietras and O. K. Weinberg Antiangiogenic Steroids in Human Cancer Therapy Evid. Based Complement. Altern. Med., March 1, 2005; 2(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Li, S. Ahmed, and J. A. Loeb Development of an Autocrine Neuregulin Signaling Loop with Malignant Transformation of Human Breast Epithelial Cells Cancer Res., October 1, 2004; 64(19): 7078 - 7085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sithanandam, G. T. Smith, A. Masuda, T. Takahashi, L. M. Anderson, and L. W. Fornwald Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway Carcinogenesis, October 1, 2003; 24(10): 1581 - 1592. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
